New York, Jan 8, 2026, 14:50 ET — Regular session
- ICON shares slide as Truist cuts rating to “hold” and trims target price
- A fresh SEC filing ties 2026 guidance to the next quarterly results
- CRO peers drift lower, but ICON’s drop stands out
ICON Public Limited Company shares fell sharply on Thursday, sliding $16.09, or about 7.9%, to $186.83 in afternoon trading after a Truist Securities downgrade knocked sentiment. Truist cut ICON to “hold” from “buy” and lowered its price target to $222 from $231, according to reports of the note. 1
The timing matters because ICON is nearing the point where it has to put numbers around 2026. In a Form 6-K dated Wednesday, the contract research group said it intends to issue full-year 2026 guidance alongside its fourth-quarter and full-year 2025 results. 2
The move was heavier than in some listed peers, suggesting the selling was company-specific. IQVIA was down about 0.4%, Medpace slipped roughly 3.2%, and Charles River Laboratories fell about 1.3% in the same session.
Truist analyst Jailendra Singh pointed to “limited visibility into cancellation levels” and margin pressure “likely to persist in 2026,” arguing the year could be “another transition year with limited growth.” He said Truist expects ICON’s 2026 EBITDA margin — EBITDA is a common proxy for operating profit — to show a 60-70 basis point headwind year-on-year (a basis point is one hundredth of a percentage point), and flagged a potentially wide initial 2026 earnings-per-share guidance range of $12-$14. 3
On the charts, some traders had been watching the $211 level as a potential breakout point before Thursday’s drop dragged the stock further away from that area, Investor’s Business Daily wrote. 4
But the next step is not technical. If cancellations stay elevated or ICON’s 2026 outlook lands below what investors have penciled in, the stock could face another leg down; the flip side is that steadier bookings and cleaner margins could blunt the downgrade’s impact.
